<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Gray zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are defined as lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> that cannot be reliably classified into a single distinct disease entity after <z:hpo ids='HP_0000001'>all</z:hpo> available morphologic, immunophenotypic, and molecular investigations have been performed </plain></SENT>
<SENT sid="1" pm="."><plain>The 2008 World Health Organization Classification proposed 2 gray zone lesions: (1) B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unclassifiable, with features intermediate between diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and (2) B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unclassifiable, with features intermediate between diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and classical Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>These gray zone lesions are rare, especially in pediatric patients, and create a great challenge to both pathologists and oncologists because this differential diagnosis has direct implications for management strategies </plain></SENT>
<SENT sid="3" pm="."><plain>In this manuscript, we report 2 cases of pediatric patients with gray zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and review clinicopathologic features, treatment options, and outcomes of this uncommon <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
</text></document>